HKMPF - Hikma gets preliminary approval from FTC to acquire Custopharm

Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) said it received preliminary approval from the U.S. Federal Trade Commission for its its acquisition of Custopharm from Water Street Healthcare Partners. The company said the parties have now obtained all regulatory approvals required to close the transaction. In September 2021, Hikma said it was acquiring U.S.-based generic sterile injectables company Custopharm to bolster the U.K.-based company's U.S. injectables business. Hikma said it would pay an initially pay $375M in cash on a debt and cash-free basis, with a further $50M in contingent consideration payable upon the achievement of certain commercial milestones.

For further details see:

Hikma gets preliminary approval from FTC to acquire Custopharm